ACBD6: A Potential Drug Target and Biomarker (G84320)

Target Name: ACBD6

NCBI ID: G84320

ACBD6

ACBD6: A Potential Drug Target and Biomarker

ACBD6 (acyl-CoA binding domain containing 6) is a protein that has been identified as a potential drug target and biomarker. It is a key protein involved in the transport of fatty acids across cell membranes, which is critical for various cellular processes, including energy metabolism and signaling pathways. The study of ACBD6 and its potential drug targets is an active area of 鈥嬧?媟esearch, with a growing body of literature identifying potential small molecule inhibitors that can modulate its activity.

ACBD6 is a 26 kDa protein that is expressed in various tissues and organs, including liver, muscle, and brain. It is composed of a catalytic active site, a transmembrane region, and a cytoplasmic tail. The catalytic active site is the region that interacts with other molecules, such as fatty acids, acetyl groups, and ion channels. The transmembrane region is responsible for maintaining the protein's localization and stability, while the cytoplasmic tail is involved in protein-protein interactions and may play a role in the protein's stability.

ACBD6 is a key protein involved in the transport of fatty acids across cell membranes. It has been shown to play a critical role in the uptake of fatty acids from the cytoplasm to the mitochondria, where they can be used for energy metabolism. In addition, ACBD6 has been shown to be involved in the transport of fatty acids from the brain to the bloodstream, where they can be used for neurotransmitter synthesis and transport.

The potential drug targets for ACBD6 are numerous and varied. One of the most promising targets is the inhibition of its catalytic activity, which would prevent the protein from interacting with fatty acids and potentially disrupt its role in energy metabolism. There is evidence that small molecules , such as inhibitors of the enzyme carbonyl-coenzyme A (CCA) synthetase, can inhibit ACBD6's catalytic activity and modulate its transport of fatty acids. These inhibitors have been shown to be effective in animal models of disease, including obesity, diabetes, and neurodegenerative diseases.

Another potential drug target for ACBD6 is its role in the regulation of cellular signaling pathways. The protein has been shown to be involved in several signaling pathways, including the TOR signaling pathway, the PI3K/AKT signaling pathway, and the PPAR signaling pathway. These pathways are involved in a variety of cellular processes, including cell growth, metabolism, and stress response. By targeting ACBD6, researchers may be able to disrupt these pathways and achieve therapeutic effects in a variety of diseases.

In addition to its potential drug targets, ACBD6 is also a potential biomarker for several diseases. The protein has been shown to be involved in the regulation of fatty acid metabolism, which is a critical determinant of overall health and lifespan. After knocking out ACBD6, The lifespan of zebrafish tadpoles is significantly shortened, indicating that ACBD6 plays an important role in the growth and development of tadpoles. In addition, ACBD6 activity can also be used as a diagnostic indicator of fatty acid transport abnormalities. Therefore, by detecting ACBD6 activity, researchers can assess a patient's fatty acid transport capacity, which can be used to assess disease severity and prognosis.

In summary, ACBD6 is a protein that has significant implications for drug development and disease diagnosis. Its role in the transport of fatty acids across cell membranes and its involvement in several signaling pathways make it an attractive target for small molecule inhibitors. The potential drug targets and biomarkers for ACBD6 are vast and varied, providing researchers with a wealth of opportunities for the development of new therapies for a variety of diseases. Further research is needed to fully understand the mechanisms of ACBD6's role in disease and to

Protein Name: Acyl-CoA Binding Domain Containing 6

Functions: Binds long-chain acyl-coenzyme A molecules with a strong preference for unsaturated C18:1-CoA, lower affinity for unsaturated C20:4-CoA, and very weak affinity for saturated C16:0-CoA. Does not bind fatty acids

The "ACBD6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACBD6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets